| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_648c9679dd9ec36125406a2dafa6bf7e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-82 |
| filingDate |
2007-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e6516f15da1f009f51544e001e302fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bebbef0a2d868e240630b13e594bc8f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f22ff92be48975a547c3fc0c40ae4993
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a758aec4305cb4afb527a5225988056a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bc5a808c53045b45c337e95f65930a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c22c12aaf975c0f3f7a4d1395bf4e56e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af7162e8042e2f7792a6b4c3d7504ffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0adeb5a3db91304bd4b2cb8df08bbb6f |
| publicationDate |
2009-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2086579-A2 |
| titleOfInvention |
Poultry vaccine, for necrotic enteritis, comprising a mutated clostridium perfringens alpha toxin antigen, and methods of producing the vaccine |
| abstract |
This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cρ) α-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cρ is also disclosed. |
| priorityDate |
2006-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |